ASX:DXB Dimerix (DXB) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Dimerix Stock (ASX:DXB) 30 days 90 days 365 days Advanced Chart Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Dimerix alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield5.16%Price TargetN/AConsensus RatingN/A Company OverviewDimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 which is in phase 2 clinical trial for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. Dimerix Limited is headquartered in Fitzroy, Australia.Read More… Download Our Tesla Ebook For Free (Ad)Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Receive DXB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dimerix and its competitors with MarketBeat's FREE daily newsletter. Email Address DXB Stock News HeadlinesCompanies Like Dimerix (ASX:DXB) Can Afford To Invest In GrowthNovember 20, 2024 | uk.finance.yahoo.comDimerix’s Phase 3 Kidney Trial Progresses SuccessfullyNovember 20, 2024 | markets.businessinsider.comYou won’t believe where OpenAI billionaire is investing nowBillionaire Sam Altman has become one of the most powerful men in the world by running OpenAI… But there’s a far lesser known investment he’s making that could put OpenAI to shame. In fact this Sam Altman-backed company could actually become a crucial partner for OpenAI… And the US Military… not to mention hundreds of other giant companies around the globe. To make the story even crazier… this company only recently became viable, thanks to an obscure piece of legislation that President Trump signed before he left office… Which ordered the government to take this incredible new technology seriously.November 29, 2024 | DTI (Ad)Dimerix Gains $7.9 Million Boost for R&D InitiativesNovember 15, 2024 | markets.businessinsider.comFive ASX healthcare companies poised for game-changing catalystsNovember 13, 2024 | msn.comASX Quarterly Health Wrap: Action for Dimerix Phase 3 kidney trialNovember 1, 2024 | msn.comDimerix links up with US NEPTUNE network to boost recruitment for FSGS studyNovember 1, 2024 | msn.comDimerix Collaborates with NEPTUNE for Trial RecruitmentNovember 1, 2024 | markets.businessinsider.comSee More Headlines DXB Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Dimerix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dimerix investors own include Immuron (IMRN), Noxopharm (NOX), Tabcorp (TAH), NexGen Energy (NXE) and Kazia Therapeutics (KZIA). Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:DXB CUSIPN/A CIKN/A Webdimerix.com Phone1.212.250.8024FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,080,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-141.42% Return on Assets-42.83% Debt Debt-to-Equity Ratio0.82 Current Ratio9.49 Quick Ratio7.91 Sales & Book Value Annual Sales$9.12 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueA$0.03 per share Price / BookN/AMiscellaneous Outstanding Shares557,130,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.53 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (ASX:DXB) was last updated on 11/29/2024 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dimerix Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Dimerix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
